The Current Ratio as of March 2025 (TTM) for Janux Therapeutics, Inc. (JANX) is 59.21

According to Janux Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 59.21. This represents a change of 8.92% compared to the average of 54.36 of the last 4 quarters.

Janux Therapeutics, Inc. (JANX) Historical Current Ratio (quarterly & annually)

How has JANX Current Ratio performed in the past?

The mean historical Current Ratio of Janux Therapeutics, Inc. over the last ten years is 23.47. The current 59.21 Current Ratio has changed 25.13% with respect to the historical average. Over the past ten years (40 quarters), JANX's Current Ratio was at its highest in in the March 2024 quarter at 62.09. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Janux Therapeutics, Inc. (JANX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Janux Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Janux Therapeutics, Inc. (JANX) Average Current Ratio

How has JANX Current Ratio performed in the past?

The current Current Ratio of Janux Therapeutics, Inc. (JANX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Janux Therapeutics, Inc. (JANX) Current Ratio vs. Peers

How is JANX’s Current Ratio compared to its peers?

Janux Therapeutics, Inc.’s Current Ratio is greater than Mineralys Therapeutics, Inc. (14.02), less than Eliem Therapeutics, Inc. (0), greater than Anebulo Pharmaceuticals, Inc. (48.18), greater than Rezolute, Inc. (9.30), greater than Keros Therapeutics, Inc. (21.45), greater than Fennec Pharmaceuticals Inc. (6.72), greater than Edgewise Therapeutics, Inc. (19.93), greater than Harmony Biosciences Holdings, Inc. (3.31), greater than Molecular Partners AG (14.31), greater than MediciNova, Inc. (13.88), greater than Champions Oncology, Inc. (0.99), greater than Cyteir Therapeutics, Inc. (21.89), greater than Aerovate Therapeutics, Inc. (20.93), greater than Adagene Inc. (2.50), greater than Acrivon Therapeutics, Inc. Common Stock (12.75), greater than AN2 Therapeutics, Inc. (8.43),

Build a custom stock screener for Janux Therapeutics, Inc. (JANX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Janux Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Janux Therapeutics, Inc. (JANX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Janux Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.